Skip to main content

Advertisement

SpringerLink
Log in

Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker

  • Review
  • Published:
Tumor Biology

Abstract

Ubiquitin-conjugating enzyme 2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of short-lived proteins. As a conjugating enzyme, it directs polyubiquitination to preferred lysine in the substrates. In addition to its well-known role in cyclin B destruction that is essential for exit from mitosis, UBE2C also plays an important role in mitotic spindle checkpoint control. Cells overexpressing UBE2C ignore the mitotic spindle checkpoint signals and lose genomic stability, which is a hallmark of cancer. UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. The level of expression correlates with the aggressiveness of the tumor. High UBE2C expression is predictive of poor survival and perhaps high risk for relapse. UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002;3(2):112–21.

    Article  PubMed  CAS  Google Scholar 

  2. Williamson A, Wickliffe KE, Mellone BG, Song L, Karpen GH, Rape M. Identification of a physiological E2 module for the human anaphase-promoting complex. Proc Natl Acad Sci USA. 2009;106(43):18213–8.

    Article  PubMed  CAS  Google Scholar 

  3. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol. 2006;22:159–80.

    Article  PubMed  CAS  Google Scholar 

  4. Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immunol. 2004;22:81–127.

    Article  PubMed  Google Scholar 

  5. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem. 2010;147(6):793–8.

    Article  PubMed  CAS  Google Scholar 

  6. Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains. Nat Rev Mol Cell Biol. 2005;6(8):610–21.

    Article  PubMed  CAS  Google Scholar 

  7. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL, et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature. 2007;446(7138):876–81.

    Article  PubMed  CAS  Google Scholar 

  8. Reddy SK, Rape M, Margansky WA, Kirschner MW. Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature. 2007;446(7138):921–5.

    Article  PubMed  CAS  Google Scholar 

  9. van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 2010;188(1):83–100.

    Article  PubMed  Google Scholar 

  10. Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA. 1997;94(6):2362–7.

    Article  PubMed  CAS  Google Scholar 

  11. Kim S, Yu H. Mutual regulation between the spindle checkpoint and APC/C. Semin Cell Dev Biol. 2011;22(6):551–8.

    Article  PubMed  CAS  Google Scholar 

  12. Nath S, Banerjee T, Sen D, Das T, Roychoudhury S. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. J Biol Chem. 2011;286(18):15666–77.

    Article  PubMed  CAS  Google Scholar 

  13. Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009;81(11):4493–501.

    Article  PubMed  CAS  Google Scholar 

  14. Rape M, Kirschner MW. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature. 2004;432(7017):588–95.

    Article  PubMed  CAS  Google Scholar 

  15. Jin L, Williamson A, Banerjee S, Philipp I, Rape M. Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex. Cell. 2008;133(4):653–65.

    Article  PubMed  CAS  Google Scholar 

  16. David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. J Biol Chem. 2010;285(12):8595–604.

    Article  PubMed  CAS  Google Scholar 

  17. Nasmyth K. How do so few control so many? Cell. 2005;120(6):739–46.

    Article  PubMed  CAS  Google Scholar 

  18. Yanagida M. Basic mechanism of eukaryotic chromosome segregation. Philos Trans R Soc Lond B Biol Sci. 2005;360(1455):609–21.

    Article  PubMed  CAS  Google Scholar 

  19. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell. 2002;13(3):755–66.

    Article  PubMed  CAS  Google Scholar 

  20. Wickliffe KE, Lorenz S, Wemmer DE, Kuriyan J, Rape M. The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2. Cell. 2011;144(5):769–81.

    Article  PubMed  CAS  Google Scholar 

  21. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116(2):221–34.

    Article  PubMed  CAS  Google Scholar 

  22. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 2000;10(10):429–39.

    Article  PubMed  CAS  Google Scholar 

  23. Jiang F, Basavappa R. Crystal structure of the cyclin-specific ubiquitin-conjugating enzyme from clam, E2-C, at 2.0 A resolution. Biochemistry. 1999;38(20):6471–8.

    Article  PubMed  CAS  Google Scholar 

  24. Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 2002;277(24):21913–21.

    Article  PubMed  CAS  Google Scholar 

  25. Summers MK, Pan B, Mukhyala K, Jackson PK. The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell. 2008;31(4):544–56.

    Article  PubMed  CAS  Google Scholar 

  26. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003;63(14):4167–73.

    PubMed  CAS  Google Scholar 

  27. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997;17(4):495–7.

    Article  PubMed  CAS  Google Scholar 

  28. Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004;350(14):1405–13.

    Article  PubMed  CAS  Google Scholar 

  29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  PubMed  CAS  Google Scholar 

  30. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2011;17(6):1490–501.

    Article  PubMed  CAS  Google Scholar 

  31. Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK, Kalna G, et al. Divergent routes to oral cancer. Cancer Res. 2006;66(15):7405–13.

    Article  PubMed  CAS  Google Scholar 

  32. Patel D, McCance DJ. Compromised spindle assembly checkpoint due to altered expression of Ubch10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J Virol. 2010;84(21):10956–64.

    Article  PubMed  CAS  Google Scholar 

  33. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, et al. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004;23(39):6621–9.

    Article  PubMed  CAS  Google Scholar 

  34. Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, et al. UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007;43(18):2729–35.

    Article  PubMed  CAS  Google Scholar 

  35. Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer. 2009;101(1):166–73.

    Article  PubMed  CAS  Google Scholar 

  36. Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, et al. UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2007;26(14):2136–40.

    Article  PubMed  CAS  Google Scholar 

  37. Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X. Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol. 2010;136(3):419–26.

    Article  PubMed  CAS  Google Scholar 

  38. Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121(1):33–8.

    Article  PubMed  CAS  Google Scholar 

  39. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, et al. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005;93(4):464–71.

    Article  PubMed  CAS  Google Scholar 

  40. Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, et al. Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 2008;1201:161–6.

    Article  PubMed  CAS  Google Scholar 

  41. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138(2):245–56.

    Article  PubMed  CAS  Google Scholar 

  42. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011;30(12):2405–19.

    Article  PubMed  CAS  Google Scholar 

  43. Garnis C, Coe BP, Lam SL, MacAulay C, Lam WL. High-resolution array CGH increases heterogeneity tolerance in the analysis of clinical samples. Genomics. 2005;85(6):790–3.

    Article  PubMed  CAS  Google Scholar 

  44. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med. 2008;8(6):446–58.

    Article  PubMed  CAS  Google Scholar 

  45. Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, et al. UbcH10 expression in human lymphomas. Histopathology. 2009;54(6):731–40.

    Article  PubMed  Google Scholar 

  46. Cunha IW, Carvalho KC, Martins WK, Marques SM, Muto NH, Falzoni R, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol. 2010;3(1):23–32.

    Article  PubMed  Google Scholar 

  47. Takahashi Y, Ishii Y, Nishida Y, Ikarashi M, Nagata T, Nakamura T, et al. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet Cytogenet. 2006;168(1):30–5.

    Article  PubMed  CAS  Google Scholar 

  48. Guerriero E, Ferraro A, Desiderio D, Pallante P, Berlingieri MT, Iaccarino A, et al. UbcH10 expression on thyroid fine-needle aspirates. Cancer Cytopathol. 2010;118(3):157–65.

    Article  PubMed  Google Scholar 

  49. Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F, Pallante PL, et al. Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. Clin Neuropathol. 2008;27(4):219–23.

    PubMed  CAS  Google Scholar 

  50. Karadag YS, Karadag O, Cicekli E, Ozturk S, Kiraz S, Ozbakir S, et al. Severity of carpal tunnel syndrome assessed with high frequency ultrasonography. Rheumatol Int. 2010;30(6):761–5.

    Article  PubMed  Google Scholar 

  51. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F, et al. Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat. 2008;109(3):491–501.

    Article  PubMed  CAS  Google Scholar 

  52. Taylor KJ, Sims AH, Liang L, Faratian D, Muir M, Walker G, et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res. 2010;12(3):R39.

    Article  PubMed  Google Scholar 

  53. Wang H, Zhang C, Rorick A, Wu D, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res. 2011;71(14):4866–76.

    Article  PubMed  CAS  Google Scholar 

  54. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005;24(33):5246–51.

    Article  PubMed  CAS  Google Scholar 

  55. Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J, et al. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol. 2011;178(5):2109–20.

    Article  PubMed  CAS  Google Scholar 

  56. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther. 2004;3(6):661–9.

    PubMed  CAS  Google Scholar 

  57. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol. 2009;161(1):141–52.

    Article  PubMed  CAS  Google Scholar 

  58. Fevre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, et al. Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol. 2009;35(6):1395–407.

    Article  PubMed  CAS  Google Scholar 

  59. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005;65(19):8679–89.

    Article  PubMed  CAS  Google Scholar 

  60. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol. 2011;5(1):77–92.

    Article  PubMed  CAS  Google Scholar 

  61. Parris TZ, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G, et al. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res. 2010;16(15):3860–74.

    Article  PubMed  CAS  Google Scholar 

  62. Chen CC, Chang TW, Chen FM, Hou MF, Hung SY, Chong IW, et al. Combination of multiple mRNA markers (PTTG1, Survivin, UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array. Oncology. 2006;70(6):438–46.

    Article  PubMed  CAS  Google Scholar 

  63. Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11:80.

    Article  PubMed  Google Scholar 

  64. Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, Rao PH, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer. 2007;46(4):373–84.

    Article  PubMed  CAS  Google Scholar 

  65. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci USA. 2009;106(17):7131–6.

    Article  PubMed  CAS  Google Scholar 

  66. Lin J, Raoof DA, Wang Z, Lin MY, Thomas DG, Greenson JK, et al. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia. 2006;8(12):1062–71.

    Article  PubMed  CAS  Google Scholar 

  67. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, et al. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009;2(8):702–11.

    Article  CAS  Google Scholar 

  68. Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, et al. Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer. 2008;15(3):801–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Georgia Health Sciences University Cancer Center, Georgia Health Sciences University, 1120 15th street, Augusta, GA, 30912, USA

    Zhonglin Hao & John Cowell

  2. Division of Hematology and Oncology, Georgia Health Sciences University, Augusta, GA, 30912, USA

    Zhonglin Hao & Hui Zhang

Authors
  1. Zhonglin Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Cowell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhonglin Hao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hao, Z., Zhang, H. & Cowell, J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol. 33, 723–730 (2012). https://doi.org/10.1007/s13277-011-0291-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0291-1

Keywords

Search

Navigation